FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis

• Status: Terminated
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• provision of written informed consent

• male or female, aged 18-65 years

• requirement of hospitalization and in need for antipsychotic treatment for an acute psychotic episode

• able to swallow tablets from Day 1

Exclusion Criteria:

• In-patients who are anticipated to be discharged before evaluation of the primary outcome variable at Day 5

• patients with known relevant clinical disease

• history of syncope, or orthostatic hypotension

• patients with known neutropenia